Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023473 (
chronic myeloid leukemia
)
18,916
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The potent clinical responses seen in patients with
chronic myeloid leukemia
(
CML
) after administration of donor-specific lymphocytes, as well as the correlation between the presence of antigen specific T cells and prolonged remission in these patients, suggests a role for the immunological control of
CML
. Here we propose
Aldara
, a clinically used formulation of imiquimod, as an agent for augmenting immune responses to
CML
antigens. Our proposition is based upon 3 tenets: 1) Endogenous dendritic cells (DC) of
CML
patients, which are known to be derived from the malignant clone, express and present various leukemic antigens; 2)
CML
-antigen reactive T cell clones exist in the patient but in many situations are ineffectively stimulated to cause significant hematological responses; and 3) Antigen presentation by mature, activated DC, which endogenously express
CML
-antigens may endow the pre-existing ineffective T cell responses with ability to control CML progression. The practical use of
Aldara
as a localized activator of DC in the context of present day leukemic therapeutics, as well as various properties of this unique immune modulator will be discussed.
...
PMID:Therapeutic use of Aldara in chronic myeloid leukemia. 1725 47
